Effectiveness and Safety of Bupropion in Children and Adolescents with Depressive Disorders: A Retrospective Chart Review
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Objective: This study aimed to investigate the effectiveness and safety of bupropion extended-release for the treatment of depressive disorder in children and adolescents. Methods: This was a 12-week, retrospective chart review of bupropion, which included 127 youth (age, 15.3 ± 2.3 years; 66 boys) with depressive disorders (105 with major depressive disorder, 14 with dysthymia, 11 with adjustment disorder with depressed mood, and seven with depressive disorder not otherwise specified). Illness severity at baseline and at the 4th, 8th, and 12th weeks was retrospectively scored using the Clinical Global Impressions-Depression-Severity (CGI-Depression-S) and/or Clinical Global Impressions-Depression-Improvement (CGI-Depression-I). Results: The mean dose of bupropion was 180.0 ± 52.6 (range, 75−300) mg/day and the mean duration 33.9 ± 53.1 (range, 7−295) weeks. The CGI-Depression-S scores were significantly decreased over 12 weeks (F = 132.125, p ＜ 0.001, partial 2 = 0.508). Fifty-eight subjects (45.7%) were determined to be responders at 12 weeks (defined by a CGI-Depression-I score ≤ 2). Forty-six patients (36.2%) discontinued bupropion before the 12 weeks (19 due to adverse events, 15 due to poor effectiveness, three due to referral to other clinics, and nine due to follow-up loss for unknown reasons). Overall, bupropion was well tolerated. The most common adverse event was irritability (n = 12, 9.4%), which resolved spontaneously in eight subjects or after drug discontinuation in four subjects. Conclusion: Our results provide preliminary evidence of the effectiveness and safety of bupropion in children and adolescents with depressive episodes. Large, prospective, placebo-controlled studies are needed to confirm these findings.
Abstract
Objective: This study aimed to investigate the effectiveness and safety of bupropion extended-release for the treatment of depressive disorder in children and adolescents. Methods: This was a 12-week, retrospective chart review of bupropion, which included 127 youth (age, 15.3 ± 2.3 years; 66 boys) with depressive disorders (105 with major depressive disorder, 14 with dysthymia, 11 with adjustment disorder with depressed mood, and seven with depressive disorder not otherwise specified). Illness severity at baseline and at the 4th, 8th, and 12th weeks was retrospectively scored using the Clinical Global Impressions-Depression-Severity (CGI-Depression-S) and/or Clinical Global Impressions-Depression-Improvement (CGI-Depression-I). Results: The mean dose of bupropion was 180.0 ± 52.6 (range, 75−300) mg/day and the mean duration 33.9 ± 53.1 (range, 7−295) weeks. The CGI-Depression-S scores were significantly decreased over 12 weeks (F = 132.125, p ＜ 0.001, partial 2 = 0.508). Fifty-eight subjects (45.7%) were determined to be responders at 12 weeks (defined by a CGI-Depression-I score ≤ 2). Forty-six patients (36.2%) discontinued bupropion before the 12 weeks (19 due to adverse events, 15 due to poor effectiveness, three due to referral to other clinics, and nine due to follow-up loss for unknown reasons). Overall, bupropion was well tolerated. The most common adverse event was irritability (n = 12, 9.4%), which resolved spontaneously in eight subjects or after drug discontinuation in four subjects. Conclusion: Our results provide preliminary evidence of the effectiveness and safety of bupropion in children and adolescents with depressive episodes. Large, prospective, placebo-controlled studies are needed to confirm these findings.
참고문헌 (16)
- "Textbook of child and adolescent mental health" (2015)[URL]
- Berigan TR, "The Many uses of bupropion and bupropion sustained release(SR)in adults", Prim Care Companion J Clin Psychiatry, 4, pp.30~32 (2002)
- Milea D, "Prescription patterns of antidepressants : findings from a US claims database", Curr Med Res Opin, 26, pp.1343~1353 (2010)
- 남범우, "Comparing the Effects of Bupropion and Escitalopram on Excessive Internet Game Play in Patients with Major Depressive Disorder", Clinical Psychopharmacology and Neuroscience, 15(4), pp.361~368 (2017), 대한정신약물학회[DOI]
- Rush AJ, "Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression", N Engl J Med, 354, pp.1231~1242 (2006)
- Post RM, "Mood switch in bipolar depression : comparison of adjunctive venlafaxine, bupropion and sertraline", Br J Psychiatry, 189, pp.124~131 (2006)
- Arredondo D, "Bupropion treatment of adolescent depression", 146th Annual Meeting of the American Psychiatric Association (1993)
- Glod CA, "Open trial of bupropion SR in adolescent major depression", J Child Adolesc Psychiatr Nurs, 16, pp.123~130 (2003)
- Daviss WB, "Bupropion sustained release in adolescents with comorbid attention-deficit", hyperactivity disorder and depression, 2001, pp.40, 307~314
- Andreasen NC, "Antipsychotic dose equivalents and dose-years : a standardized method for comparing exposure to different drugs", Biol Psychiatry, 67, pp.255~262 (2010)
- Guy W, "Clinical global impression scale, ECDEU Assessment Manual for Psychopharmacology, revised (DHEW Publ. No. ADM 76-338)", National Institute of Mental Health, ~ (1976)
- Rating-scales and assessment instruments for use in pediatric psychopharmacology researchintroduction, "Rapoport J", US Government Printing Office Superintendent of Documents, ~ (1985)
- Goldberg JF, "Antidepressant‐induced mania : an overview of current controversies", Bipolar Disord, 5, pp.407~420 (2003)
- Hetrick S, "Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents", Cochrane Database Syst Rev, (3), pp.CD004851~ (2007)
- Ng QX, "A systematic review of the use of bupropion for attention-deficit", hyperactivity disorder in children and adolescents, 2017, pp.27, 112~116
- Emslie G, "Treatment for Adolescents with Depression Study(TADS) : safety results", J Am Acad Child Adolesc Psychiatry, 45, pp.1440~1455 (2006)